Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $82
CG Oncology, Inc.
CG Oncology, Inc. CGON | 0.00 |
Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:
CGON) with a Buy and raises the price target from $77 to $82.
